Revenue Breakdown
Composition ()
No data
Revenue Streams
Sarepta Therapeutics Inc (SRPT) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is PMO Products, accounting for 59.7% of total sales, equivalent to $238.54M. Other significant revenue streams include ELEVIDYS and collaboration and other. Understanding this composition is critical for investors evaluating how SRPT navigates market cycles within the Pharmaceuticals industry.
Profitability & Margins
Evaluating the bottom line, Sarepta Therapeutics Inc maintains a gross margin of 9.83%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -92.58%, while the net margin is -93.07%. These profitability ratios, combined with a Return on Equity (ROE) of -53.47%, provide a clear picture of how effectively SRPT converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, SRPT competes directly with industry leaders such as ZYME and AGIO. With a market capitalization of $1.71B, it holds a significant position in the sector. When comparing efficiency, SRPT's gross margin of 9.83% stands against ZYME's 100.00% and AGIO's 90.59%. Such benchmarking helps identify whether Sarepta Therapeutics Inc is trading at a premium or discount relative to its financial performance.
